Legend Holdings joined existing backers including Eli Lilly, Fidelity Biosciences and Fidelity for drug developer Innovent's series C
China-based pharmaceutical company Innovent Biologics has received $100m from a series C round led by Legend Capital, the corporate venturing arm of conglomerate Legend Holdings, Fierce Biotech reported yesterday.
Pharmaceutical company Eli Lilly also participated in the round, alongside financial services provider Fidelity Worldwide Investment’s biotech venturing arm Fidelity Biosciences, Fidelity’s China-based venture capital unit Fidelity Growth Partners Asia and Frontline Bioventures.
Eli Lilly, Fidelity Growth Partners Asia and Fidelity Biosciences previously funded a $25m series B round for Innovent…
